Testing effectiveness (Phase 2)Temporarily pausedNCT06202066
What this trial is testing
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas
Who this might be right for
Digestive System Neuroendocrine NeoplasmLung Neuroendocrine NeoplasmMalignant Solid Neoplasm+1 more
Roswell Park Cancer Institute 60